Research programme: CD40L inhibitors - Psivant Therapeutics
Latest Information Update: 13 Mar 2025
At a glance
- Originator Psivant Therapeutics
- Class Anti-inflammatories; Small molecules
- Mechanism of Action CD40 ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Immunological disorders; Inflammation
Most Recent Events
- 28 Jan 2025 Early research in Immunological disorders (PO) prior to January 2024, (Psivant Therapeutics pipeline, January 2024)
- 28 Jan 2025 Early research in Inflammation (PO) prior to January 2024, (Psivant Therapeutics pipeline, January 2024)